In our phase 3 , randomized , double-blind , multicenter study involving patients with progressive thyroid cancer that was refractory to iodine-131 , we randomly assigned 261 patients to receive lenvatinib ( at a daily dose of 24 mg per day in 28-day cycles ) and 131 patients to receive placebo .